vs
Side-by-side financial comparison of ARGENX SE (ARGX) and Celanese Corp (CE). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $2.2B, roughly 1.1× Celanese Corp). ARGENX SE runs the higher net margin — 35.5% vs 0.6%, a 34.8% gap on every dollar of revenue. On growth, ARGENX SE posted the faster year-over-year revenue change (83.2% vs -7.0%). ARGENX SE produced more free cash flow last quarter ($322.4M vs $168.0M).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).
ARGX vs CE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $2.2B |
| Net Profit | $877.2M | $14.0M |
| Gross Margin | 89.5% | 19.1% |
| Operating Margin | 28.9% | 4.0% |
| Net Margin | 35.5% | 0.6% |
| Revenue YoY | 83.2% | -7.0% |
| Net Profit YoY | 1.3% | 100.7% |
| EPS (diluted) | $13.25 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5B | $2.2B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | $1.4B | $2.4B | ||
| Q3 24 | — | $2.6B | ||
| Q2 24 | $901.9M | $2.7B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | $877.2M | $14.0M | ||
| Q3 25 | — | $-1.4B | ||
| Q2 25 | $414.8M | $199.0M | ||
| Q1 25 | — | $-21.0M | ||
| Q4 24 | $865.6M | $-1.9B | ||
| Q3 24 | — | $116.0M | ||
| Q2 24 | $-32.5M | $155.0M | ||
| Q1 24 | — | $121.0M |
| Q4 25 | 89.5% | 19.1% | ||
| Q3 25 | — | 21.5% | ||
| Q2 25 | 89.2% | 21.1% | ||
| Q1 25 | — | 19.9% | ||
| Q4 24 | 90.2% | 22.7% | ||
| Q3 24 | — | 23.5% | ||
| Q2 24 | 89.4% | 24.2% | ||
| Q1 24 | — | 21.2% |
| Q4 25 | 28.9% | 4.0% | ||
| Q3 25 | — | -52.7% | ||
| Q2 25 | 19.2% | 9.2% | ||
| Q1 25 | — | 7.0% | ||
| Q4 24 | 8.7% | -59.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | -15.4% | 9.4% | ||
| Q1 24 | — | 8.0% |
| Q4 25 | 35.5% | 0.6% | ||
| Q3 25 | — | -56.1% | ||
| Q2 25 | 23.4% | 7.9% | ||
| Q1 25 | — | -0.9% | ||
| Q4 24 | 64.1% | -80.8% | ||
| Q3 24 | — | 4.4% | ||
| Q2 24 | -3.6% | 5.8% | ||
| Q1 24 | — | 4.6% |
| Q4 25 | $13.25 | $0.13 | ||
| Q3 25 | — | $-12.39 | ||
| Q2 25 | $6.32 | $1.81 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | $13.33 | $-17.50 | ||
| Q3 24 | — | $1.06 | ||
| Q2 24 | $-0.55 | $1.41 | ||
| Q1 24 | — | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | — |
| Total DebtLower is stronger | — | $11.4B |
| Stockholders' EquityBook value | $7.3B | $4.0B |
| Total Assets | $8.7B | $21.7B |
| Debt / EquityLower = less leverage | — | 2.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $11.4B | ||
| Q3 25 | — | $11.7B | ||
| Q2 25 | — | $12.7B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | — | $11.1B | ||
| Q3 24 | — | $11.3B | ||
| Q2 24 | $11.0M | $11.1B | ||
| Q1 24 | — | $11.0B |
| Q4 25 | $7.3B | $4.0B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | $6.1B | $5.3B | ||
| Q1 25 | — | $5.2B | ||
| Q4 24 | $5.5B | $5.2B | ||
| Q3 24 | — | $7.3B | ||
| Q2 24 | $4.3B | $7.2B | ||
| Q1 24 | — | $7.1B |
| Q4 25 | $8.7B | $21.7B | ||
| Q3 25 | — | $22.2B | ||
| Q2 25 | $7.2B | $23.7B | ||
| Q1 25 | — | $23.2B | ||
| Q4 24 | $6.2B | $22.9B | ||
| Q3 24 | — | $25.9B | ||
| Q2 24 | $4.8B | $25.8B | ||
| Q1 24 | — | $26.0B |
| Q4 25 | — | 2.81× | ||
| Q3 25 | — | 2.95× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | — | 2.14× | ||
| Q3 24 | — | 1.56× | ||
| Q2 24 | 0.00× | 1.54× | ||
| Q1 24 | — | 1.56× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $323.3M | $252.0M |
| Free Cash FlowOCF − Capex | $322.4M | $168.0M |
| FCF MarginFCF / Revenue | 13.0% | 7.6% |
| Capex IntensityCapex / Revenue | 0.0% | 3.8% |
| Cash ConversionOCF / Net Profit | 0.37× | 18.00× |
| TTM Free Cash FlowTrailing 4 quarters | $594.5M | $803.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $323.3M | $252.0M | ||
| Q3 25 | — | $447.0M | ||
| Q2 25 | $361.8M | $410.0M | ||
| Q1 25 | — | $37.0M | ||
| Q4 24 | $41.9M | $494.0M | ||
| Q3 24 | — | $79.0M | ||
| Q2 24 | $-124.7M | $292.0M | ||
| Q1 24 | — | $101.0M |
| Q4 25 | $322.4M | $168.0M | ||
| Q3 25 | — | $383.0M | ||
| Q2 25 | $356.6M | $317.0M | ||
| Q1 25 | — | $-65.0M | ||
| Q4 24 | $40.9M | $389.0M | ||
| Q3 24 | — | $-9.0M | ||
| Q2 24 | $-125.5M | $187.0M | ||
| Q1 24 | — | $-36.0M |
| Q4 25 | 13.0% | 7.6% | ||
| Q3 25 | — | 15.8% | ||
| Q2 25 | 20.1% | 12.5% | ||
| Q1 25 | — | -2.7% | ||
| Q4 24 | 3.0% | 16.4% | ||
| Q3 24 | — | -0.3% | ||
| Q2 24 | -13.9% | 7.1% | ||
| Q1 24 | — | -1.4% |
| Q4 25 | 0.0% | 3.8% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 0.3% | 3.7% | ||
| Q1 25 | — | 4.3% | ||
| Q4 24 | 0.1% | 4.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | 0.1% | 4.0% | ||
| Q1 24 | — | 5.2% |
| Q4 25 | 0.37× | 18.00× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.87× | 2.06× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 1.88× | ||
| Q1 24 | — | 0.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARGX
Segment breakdown not available.
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
